Latest News

Adding venetoclax to transplant conditioning regimen shows promise in patients with myeloid cancers

For patients with high-risk myeloid cancers undergoing a donor stem cell transplant, adding the targeted drug venetoclax to a reduced-intensity drug regimen prior to transplant is safe and does not impair the ability of the donor cells to take root in recipients’ bodies, a study led by Dana-Farber Cancer Institute researchers suggests.

Source link

Related posts

Box Chooses Collective Health to Empower Better Health Benefits


Bouncing and 3D printable hybrids with self-healing properties


Medical News Today: Autoimmune arthritis: Types, symptoms, and treatment


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World